Clinical Trial

A Single Ascending Dose of HRS-2162 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-19.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07195604
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Reversal of Neuromuscular Blockade
Enrollment 64 participants
Start Date 2025-09-25
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-17